ClinicalTrials.gg
TerminatedNCT03822117Updated Nov 4, 2025Results posted

Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)

A Phase 2 interventional study of Pemigatinib in Solid Tumor Malignancy, sponsored by Incyte Corporation. Terminated at 90 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-04.

Sponsored by Incyte Corporation · Phase 2, Interventional, and Treatment

Why this study was terminated
A business decision was made to to discontinue further enrollment. There were no safety concerns that contributed to this decision.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
111
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 16 studies in Acrocephalosyndactylia with a site in United States — none open to participants now, 1 under way, none of them phase 3. Acrocephalosyndactylia · United States.

Enrollment
4th of 14
111 · median 44
Started
2019
with 2 others
Phase 2
8 of 16
none open now
Registered
10th of 16
by date
Lead sponsor
6 of 16
Incyte Corporation

Among the 16 studies in Acrocephalosyndactylia with a site in United States, this one is the 4th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2019, is one of 8 in phase 2, and was the 10th registered.

Acrocephalosyndactylia

33 studies on the registry are indexed under Acrocephalosyndactylia; 6 are open to participants now.

Browse Acrocephalosyndactylia studies →

Open to participants now

None of the 16 studies in Acrocephalosyndactylia with a site in United States is open now. The open studies under Acrocephalosyndactylia, anywhere →

Who these studies take

Of the 5 Acrocephalosyndactylia studies recruiting now, 4 set no upper age limit and 1 stops at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 16 studies in Acrocephalosyndactylia with a site in United States as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR mutations or translocations.

03

Conditions studied

  • Solid Tumor Malignancy

Browse trials for

Keywords

  • Fibroblast growth factor receptor (FGFR) inhibitor
  • FGFR mutations
  • FGFR translocations
  • solid tumor malignancy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • or cytologically confirmed solid tumor that is advanced or or is surgically unresectable.
  • Radiographically (per v1.1 or RANO for primary brain tumors). Tumor lesions located in a previously irradiated area or in an area subjected to other loco-regional therapy are considered measureable if progression has been clearly demonstrated in the lesion.
  • Documentation of an FGFR1-3 gene mutation or translocation.
  • Objective progression after at least 1 prior therapy and no therapy available that is likely to provide clinical benefit. Participants who are intolerant to or decline the approved therapy are eligible only if they have no therapy available that is likely to provide clinical benefit.
  • performance status 0 to 2.
  • Baseline (if less than 24 months from date of screening) or willingness to undergo a pretreatment tumor biopsy to obtain the specimen. Must be a tumor block or approximately 15 unstained slides from biopsy or resection of primary tumor or metastasis.
  • Willingness to avoid pregnancy or fathering children.

Exclusion criteria

Exclusion Criteria:

  • Prior receipt of a selective FGFR inhibitor in the past 6 months.
  • Receipt of anticancer medications or drugs for any indication or reason within 28 days before first dose of pemigatinib.
  • Cannot be a candidate for potentially curative surgery.
  • Current evidence of corneal or retinal disorder as confirmed by ophthalmologic examination.
  • Radiation therapy administered within 2 weeks of enrollment/first dose of study treatment.
  • Untreated brain or central nervous system (CNS) or brain or that have progressed (eg, evidence of new or enlarging brain metastasis or new neurological symptoms attributable to brain or CNS metastases).
  • Known additional that is progressing or requires active treatment.
  • History of calcium and phosphate hemostasis disorder or systemic mineral imbalance with ectopic calcification of soft tissues.
  • Clinically significant or uncontrolled cardiac disease.
  • Active chronic or current infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment within 2 weeks before enrollment (participants with asymptomatic chronic infections on prophylactic treatment are allowed).
  • Evidence of active virus (HBV) or virus (HCV) infection (defined as elevated transaminases or cirrhosis; chronic HBV/HCV infection with no cirrhosis and no elevated transaminases is allowed).
  • Known infection.
  • Use of any potent inhibitors or inducers or moderate CYP3A4 inducers within 14 days or five half-lives (whichever is longer) before the first dose of study drug/treatment.
  • Women who are pregnant or breastfeeding.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
111 participants (actual)

Study arms

  • Experimental
    Pemigatinib

    Cohort A (Solid tumor malignancies with FGFR1-3 in frame fusions; any FGFR2 rearrangement; FGFR1/3 rearrangement with known partner\*). Cohort B (Solid tumor malignancies with known or likely activating mutations (excluding kinase domain) in FGFR1-3) Cohort C (Solid tumor malignancies with FGFR1-3 known activating mutations in kinase domain; FGFR1-3 putatively activating mutations; other FGFR1/3 rearrangements\* (not eligible for Cohort A)). \*Only FGFR fusions or rearrangements with an intact kinase domain are eligible

    Drug: Pemigatinib

Interventions

  • Pemigatinib administered orally once daily (QD).

    Also known as: INCB054828

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements

    Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1): CR: disappearance of all target/non-target lesions; no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters; no new lesions; no progression of non-target lesions. Per Response Assessment in Neuro-Oncology (RANO; for participants with primary brain tumors): CR: disappearance of all enhancing lesions; stable/improved non-enhancing lesions; stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable enhancing lesions; no progression of non-measurable disease; stable/improved non-enhancing lesions; stable/improved clinically. Cohort determination was based on FGFR status from a central genomics laboratory. Response data were from an independent centralized radiological review committee per RECIST v1.1 and RANO, and response was confirmed.

    Time frame: up to 483 days

  2. ORR, Defined as the Percentage of Participants With a Best Overall Response of CR or PR Based on RECIST v1.1 or RANO, in Participants With Known or Likely Activating FGFR1-3 Mutations

    Per RECIST v1.1: CR: disappearance of all target/non-target lesions; no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters; no new lesions; no progression of non-target lesions. Per RANO (for participants with primary brain tumors): CR: disappearance of all enhancing lesions; stable/improved non-enhancing lesions; stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable enhancing lesions; no progression of non-measurable disease; stable/improved non-enhancing lesions; stable/improved clinically. Cohort determination was based on FGFR status from a central genomics laboratory. Response data were from an independent centralized radiological review committee per RECIST v1.1 and RANO, and response was confirmed.

    Time frame: up to 449 days

Secondary outcomes

  1. Progression-free Survival (PFS) in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations

    PFS was defined as the time from the first dose until progressive disease (according to RECIST v1.1 or RANO for participants with primary brain tumors and assessed by an independent centralized radiological review committee) or death (whichever occurred first).

    Time frame: up to 532 days

  2. Duration of Response (DOR), Defined as the First CR or PR Assessment Until Progressive Disease (PD) or Death, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations

    Assessment was by an independent centralized radiological review committee; response was confirmed. Per RECIST v1.1: CR: disappearance of all target (TLs)/non-target lesions (NTLs); no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of TLs, taking as a reference the baseline sum diameters; no new lesions; no progression of NTLs. PD: progression of a TL/NTL or presence of new lesion. Per RANO (participants with primary brain tumors): CR: disappearance of all enhancing lesions (ELs); stable/improved non-enhancing lesions (NELs); stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable ELs; no progression of non-measurable disease; stable/improved NELs; stable/improved clinically. PD: \>25% increase in sum of perpendicular diameters of all measurable ELs; significant increase of NELs; new lesions; clear clinical deterioration; failure to return for evaluation due to death/deteriorating condition.

    Time frame: up to 24.90 months

  3. Overall Survival in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations

    Overall survival was defined as the time from the first dose of study drug to death of any cause.

    Time frame: up to 532 days

  4. Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-related Adverse Event (AE)

    An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. TEAEs were defined as AEs reported for the first time or the worsening of pre-existing events after the first dose of study treatment. Treatment-related AEs were defined as TEAEs judged as related by the investigator or with a missing causality.

    Time frame: up to 651 days

07

Results

Posted Mar 15, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOther
Started4932264
Completed0000
Not completed4932264
Withdrew: Death1817124
Withdrew: Lost to follow-up1230
Withdrew: Study terminated by sponsor251160
Withdrew: Withdrawal by subject4030
Withdrew: Disease progression1210
Withdrew: Never returned to hospital0010

Outcome measures

PrimaryObjective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements

Per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1): CR: disappearance of all target/non-target lesions; no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters; no new lesions; no progression of non-target lesions. Per Response Assessment in Neuro-Oncology (RANO; for participants with primary brain tumors): CR: disappearance of all enhancing lesions; stable/improved non-enhancing lesions; stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable enhancing lesions; no progression of non-measurable disease; stable/improved non-enhancing lesions; stable/improved clinically. Cohort determination was based on FGFR status from a central genomics laboratory. Response data were from an independent centralized radiological review committee per RECIST v1.1 and RANO, and response was confirmed.

Time frame:
up to 483 days
Reported as:
Number · percentage of participants
Objective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements
percentage of participantsCohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOther
Objective Response Rate (ORR), Defined as the Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) Based on RECIST v1.1 or RANO, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements26.5 (14.95 to 41.08)———
PrimaryORR, Defined as the Percentage of Participants With a Best Overall Response of CR or PR Based on RECIST v1.1 or RANO, in Participants With Known or Likely Activating FGFR1-3 Mutations

Per RECIST v1.1: CR: disappearance of all target/non-target lesions; no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of target lesions, taking as a reference the baseline sum diameters; no new lesions; no progression of non-target lesions. Per RANO (for participants with primary brain tumors): CR: disappearance of all enhancing lesions; stable/improved non-enhancing lesions; stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable enhancing lesions; no progression of non-measurable disease; stable/improved non-enhancing lesions; stable/improved clinically. Cohort determination was based on FGFR status from a central genomics laboratory. Response data were from an independent centralized radiological review committee per RECIST v1.1 and RANO, and response was confirmed.

Time frame:
up to 449 days
Reported as:
Number · percentage of participants
ORR, Defined as the Percentage of Participants With a Best Overall Response of CR or PR Based on RECIST v1.1 or RANO, in Participants With Known or Likely Activating FGFR1-3 Mutations
percentage of participantsCohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOther
ORR, Defined as the Percentage of Participants With a Best Overall Response of CR or PR Based on RECIST v1.1 or RANO, in Participants With Known or Likely Activating FGFR1-3 Mutations—9.4 (1.98 to 25.02)——
SecondaryProgression-free Survival (PFS) in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations

PFS was defined as the time from the first dose until progressive disease (according to RECIST v1.1 or RANO for participants with primary brain tumors and assessed by an independent centralized radiological review committee) or death (whichever occurred first).

Time frame:
up to 532 days
Reported as:
Median · months
Progression-free Survival (PFS) in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations
monthsCohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOther
Progression-free Survival (PFS) in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations4.53 (3.58 to 6.28)3.68 (2.07 to 4.47)——
SecondaryDuration of Response (DOR), Defined as the First CR or PR Assessment Until Progressive Disease (PD) or Death, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations

Assessment was by an independent centralized radiological review committee; response was confirmed. Per RECIST v1.1: CR: disappearance of all target (TLs)/non-target lesions (NTLs); no appearance of new lesions. PR: complete disappearance or a ≥30% decrease in the sum of the diameters of TLs, taking as a reference the baseline sum diameters; no new lesions; no progression of NTLs. PD: progression of a TL/NTL or presence of new lesion. Per RANO (participants with primary brain tumors): CR: disappearance of all enhancing lesions (ELs); stable/improved non-enhancing lesions (NELs); stable/improved clinically. PR: ≥50% decrease in sum of perpendicular diameters of measurable ELs; no progression of non-measurable disease; stable/improved NELs; stable/improved clinically. PD: \>25% increase in sum of perpendicular diameters of all measurable ELs; significant increase of NELs; new lesions; clear clinical deterioration; failure to return for evaluation due to death/deteriorating condition.

Time frame:
up to 24.90 months
Reported as:
Median · months
Duration of Response (DOR), Defined as the First CR or PR Assessment Until Progressive Disease (PD) or Death, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations
monthsCohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOther
Duration of Response (DOR), Defined as the First CR or PR Assessment Until Progressive Disease (PD) or Death, in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations7.79 (4.17 to NA)6.93 (4.01 to NA)——
SecondaryOverall Survival in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations

Overall survival was defined as the time from the first dose of study drug to death of any cause.

Time frame:
up to 532 days
Reported as:
Median · months
Overall Survival in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations
monthsCohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOther
Overall Survival in Participants With FGFR1-3 In-frame Fusions or FGFR2 Arrangements and in Participants With Known or Likely Activating FGFR1-3 Mutations17.48 (7.79 to NA)11.37 (6.57 to NA)——
SecondaryNumber of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-related Adverse Event (AE)

An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug-related. An AE could be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study treatment. TEAEs were defined as AEs reported for the first time or the worsening of pre-existing events after the first dose of study treatment. Treatment-related AEs were defined as TEAEs judged as related by the investigator or with a missing causality.

Time frame:
up to 651 days
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment-emergent Adverse Event (TEAE) and Any Treatment-related Adverse Event (AE)
ParticipantsCohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOther
TEAEs4932264
Treatment-related AEs4632264

Adverse events

Collected over up to 651 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A: FGFR1-3 In-frame Fusions or FGFR2 Arrangements18/49 (36.7%)21/49 (42.9%)49/49 (100%)
Cohort B: Known or Likely Activating FGFR1-3 Mutations17/32 (53.1%)7/32 (21.9%)32/32 (100%)
Cohort C: Other FGFR Mutations or Arrangements13/26 (50%)10/26 (38.5%)26/26 (100%)
Other4/4 (100%)2/4 (50%)4/4 (100%)
Total52/111 (46.8%)40/111 (36%)111/111 (100%)
Most frequent serious events
Showing 10 of 50
Most frequent serious events
EventCohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOtherTotal
CholangitisHepatobiliary disorders0/490/320/261/41/111
DehydrationMetabolism and nutrition disorders0/490/320/261/41/111
LymphopeniaBlood and lymphatic system disorders0/490/320/261/41/111
General physical health deteriorationGeneral disorders0/491/322/260/43/111
HypercalcaemiaMetabolism and nutrition disorders0/490/322/260/42/111
VomitingGastrointestinal disorders0/490/322/260/42/111
Abdominal painGastrointestinal disorders3/490/320/260/43/111
Confusional statePsychiatric disorders2/490/320/260/42/111
HaematemesisGastrointestinal disorders2/490/320/260/42/111
SepsisInfections and infestations2/490/320/260/42/111
Most frequent other events
Showing 10 of 87
Most frequent other events
EventCohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOtherTotal
HyperphosphataemiaMetabolism and nutrition disorders45/4927/3217/264/493/111
StomatitisGastrointestinal disorders27/4917/3213/262/459/111
AlopeciaSkin and subcutaneous tissue disorders20/4917/328/260/445/111
DiarrhoeaGastrointestinal disorders19/4917/327/260/443/111
NauseaGastrointestinal disorders11/498/326/262/427/111
PyrexiaGeneral disorders2/493/321/262/48/111
DysgeusiaNervous system disorders10/4914/326/260/430/111
ConstipationGastrointestinal disorders18/4913/326/260/437/111
Decreased appetiteMetabolism and nutrition disorders10/4912/325/260/427/111
ArthralgiaMusculoskeletal and connective tissue disorders11/4911/321/260/423/111

Baseline characteristics

Age, Continuous
Age, Continuous(years)Cohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOtherTotal
Mean59.4 ± 11.5166.0 ± 10.0461.5 ± 13.3248.0 ± 14.4561.4 ± 12.11
Sex: Female, Male
Sex: Female, Male(Participants)Cohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOtherTotal
Female281914162
Male211312349
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOtherTotal
White382016074
Black or African American00101
Asian997429
Participant Declined to Provide10001
Not Available01001
Not Required in Country of Origin01001
Missing11204
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort A: FGFR1-3 In-frame Fusions or FGFR2 ArrangementsCohort B: Known or Likely Activating FGFR1-3 MutationsCohort C: Other FGFR Mutations or ArrangementsOtherTotal
Hispanic or Latino11103
Not Hispanic or Latino442520392
Not Reported22318
Unknown12003
Captured as "Other"01001
Missing11204
08

Study locations

90 sites
  • Cancer Treatment Centers of America
    Goodyear, Arizona 85338, United States
  • Mayo Clinic Hospital
    Phoenix, Arizona 85054, United States
  • The University of Arizona Cancer Center
    Tucson, Arizona 85724, United States
  • Chao Family Comprehensive Cancer Center University of California, Irvine
    Orange, California 92868, United States
  • Stanford Cancer Center
    Palo Alto, California 94304, United States
  • John Wayne Cancer Institute
    Santa Monica, California 90404, United States
  • St. Joseph Heritage Healthcare
    Santa Rosa, California 95403, United States
  • Florida Cancer Specialists & Research Institute
    Fort Myers, Florida 33901, United States
  • Mayo Clinic Jacksonville
    Jacksonville, Florida 32224, United States
  • Florida Cancer Specialists
    St. Petersburg, Florida 33705, United States
  • Florida Cancer Specialists
    Tallahassee, Florida 32308, United States
  • Florida Cancer Specialists
    West Palm Beach, Florida 33401, United States
  • Illinois Cancer Specialists
    Arlington Heights, Illinois 60005, United States
  • Edward H Kaplan & Associates
    Skokie, Illinois 60076, United States
  • Carle Cancer Center
    Urbana, Illinois 61801, United States
  • Cancer Treatment Centers of America
    Zion, Illinois 60099, United States
  • Indiana University Health - Arnett Cancer Care
    Lafayette, Indiana 47904, United States
  • University of Iowa
    Iowa City, Iowa 52242, United States
  • University of Kansas Cancer Center
    Westwood, Kansas 66205, United States
  • Ochsner Clinic
    New Orleans, Louisiana 70121, United States
  • Central Maine Medical Center
    Lewiston, Maine 04240, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Umass Memorial Medical Center, Inc.
    Worcester, Massachusetts 01655, United States
  • Mayo Clinic Rochester
    Rochester, Minnesota 55905, United States
  • Comprehensive Cancer Centers of Nevada
    Las Vegas, Nevada 89148, United States
  • Dartmouth Hitchcock Medical Center
    Lebanon, New Hampshire 03756, United States
  • Summit Medical Group
    Florham Park, New Jersey 07932, United States
  • Winthrop University Hospital
    Mineola, New York 11501, United States
  • Oncology Specialists of Charlotte
    Charlotte, North Carolina 28204, United States
  • Duke Cancer Center
    Durham, North Carolina 27710, United States
  • Wake Forest Baptist Medical Center
    Winston-Salem, North Carolina 27157, United States
  • Stephenson Cancer Center
    Oklahoma City, Oklahoma 73104, United States
  • Southwestern Regional Medical Center
    Tulsa, Oklahoma 74133, United States
  • Cancer Institute of Greenville Health System
    Greenville, South Carolina 29605, United States
  • The West Clinic Pc
    Germantown, Tennessee 38138, United States
  • University of Texas Southwestern Medical Center
    Dallas, Texas 75390, United States
  • Houston Methodist Hospital
    Houston, Texas 77030, United States
  • Joe Arrington Cancer Center
    Lubbock, Texas 79410, United States
  • Virginia Cancer Specialists, Pc
    Fairfax, Virginia 22031, United States
  • Virginia Oncology Associates-Lake Wright
    Norfolk, Virginia 23502, United States
  • Seattle Cancer Care Alliance
    Seattle, Washington 98109, United States
  • Multicare Institute For Research & Innovation
    Tacoma, Washington 98405, United States
  • West Virginia University Hospitals Inc
    Morgantown, West Virginia 26506, United States
  • University of Wisconsin Carbone Cancer Center
    Madison, Wisconsin 53792, United States
  • The Finsen Centre National Hospital
    Copenhagen, 02100, Denmark
  • Institut Bergonie
    Bordeaux, 33000, France
  • CENTRE GEORGES FRAN�OIS LECLERC
    Dijon, 21079, France
  • Centre Antoine Lacassagne
    Nice, 06189, France
  • Hospital Saint Louis
    Paris, 75010, France
  • A.P.H. Paris Hopital Cochin
    Paris, 75014, France
  • Institut Universitaire Du Cancer de Toulouse Oncopole
    Toulouse, 31059, France
  • Universitatsklinikum Koln
    Cologne, 50937, Germany
  • University Medical Center Freiburg
    Freiburg im Breisgau, 79106, Germany
  • University Medical Centre Hamburg-Eppendorf, Centre of Oncology
    Hamburg, 20246, Germany
  • University Hospital Grosshadern Munich
    Munich, 81377, Germany
  • Universitaetsklinikum in Tubingen
    Tübingen, 72076, Germany
  • Ha Emek Medical Center
    Afula, 18101, Israel
  • Rambam Health Care Campus
    Haifa, 3525408, Israel
  • Hadassah Hebrew University Medical Center Ein Karem Hadassah
    Jerusalem, 90000, Israel
  • Rabin Medical Center - Beilinson Hospital
    Petah Tikva, 4841492, Israel
  • Assaf Harofeh Medical Center
    Ẕerifin, 7030000, Israel
  • L AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA POLICLINICO S. ORSOLA � MALPIGHI
    Bologna, 40138, Italy
  • Fondazione Del Piemonte Per L Oncologia Ircc Candiolo
    Candiolo, 10060, Italy
  • Fondazione Irccs Istituto Nazionale Dei Tumori
    Milan, 20133, Italy
  • Istituto Nazionale Tumori Irccs Fondazione Pascale
    Naples, 80131, Italy
  • Istituto Nazionale Tumori Regina Elena Irccs
    Roma, 00144, Italy
  • Centro Ricerche Cliniche Di Verona (Crc)
    Verona, 37134, Italy
  • National Hospital Organization Kyushu Cancer Center
    Fukuoka, 811-1395, Japan
  • Kanazawa University Hospital
    Ishikawa, 920-8641, Japan
  • Kobe University Hospital
    Kobe, 650-0017, Japan
  • Tohoku University Hospital
    Sendai, 980-8574, Japan
  • Keio University Hospital
    Shinjuku-ku, 160-8582, Japan
  • Shizuoka Cancer Center
    Shizuoka, 411-8777, Japan
  • Kanagawa Cancer Center
    Yokohama, 241-8515, Japan
  • National Cancer Center
    Goyang-si, 10408, South Korea
  • Seoul National University Bundang Hospital
    Seongnam-si, 13620, South Korea
  • Severance Hospital Yonsei University Health System
    Seoul, 03722, South Korea
  • Samsung Medical Center
    Seoul, 06351, South Korea
  • Hospital General Universitario Vall D Hebron
    Barcelona, 08035, Spain
  • Hospital Clinic I Provincial
    Barcelona, 08036, Spain
  • Centro Integral Oncologico Clara Campal (Ciocc)
    Madrid, 28050, Spain
  • Hospital Regional Universitario de Malaga
    Málaga, 29010, Spain
  • Clinica Universidad de Navarra (Cun)
    Pamplona, 31008, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, 39008, Spain
  • Hospital Universitario Y Politcnico de La Fe
    Valencia, 46026, Spain
  • Inselspital - Universitaetsspital Bern
    Bern, 03010, Switzerland
  • Universitatsspital Zurich
    Zurich, 08091, Switzerland
  • University College London Hospitals (Uclh)
    London, NW1 2PG, United Kingdom
  • Imperial College Healthcare Nhs Trust - Hammersmith Hospital
    London, W12 0HS, United Kingdom
  • Sarah Cannon Research Institute
    London, W1G 6AD, United Kingdom
09

References and documents

Publications

  • Rodon J, Damian S, Furqan M, Garcia-Donas J, Imai H, Italiano A, Spanggaard I, Ueno M, Yokota T, Veronese ML, Oliveira N, Li X, Gilmartin A, Schaffer M, Goyal L. Pemigatinib in previously treated solid tumors with activating FGFR1-FGFR3 alterations: phase 2 FIGHT-207 basket trial. Nat Med. 2024 Jun;30(6):1645-1654. doi: 10.1038/s41591-024-02934-7. Epub 2024 May 6. PubMed 38710951 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Incyte shares data with qualified external researchers after a research proposal is submitted. These requests are reviewed and approved by a review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. The trial data availability is according to the criteria and process described on https://www.incyte.com/our-company/compliance-and-transparency

Supporting information: Study protocol, Statistical analysis plan

Time frame: Data will be shared after the primary publication or 2 years after the study has ended for market authorized products and indications.

Access criteria: Data from eligible studies will be shared with qualified researchers according to the criteria and process described in the Data Sharing section of the www.incyteclinicaltrials.com website. For approved requests, the researchers will be granted access to anonymized data under the terms of a data sharing agreement.

Data sharing details ↗ · www.incyte.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2019 to primary completion in Mar 2022, 29 months.

Results were first posted in Mar 2023, 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 28, 2019
First posted
Jan 30, 2019
StartActual
Oct 17, 2019
Primary completionActual
Mar 29, 2022
CompletionActual
Mar 29, 2022
Results first posted
Mar 15, 2023
Last update
Nov 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03822117
Lead sponsor
Incyte Corporation
Responsible party
Sponsor
First posted
Jan 30, 2019
Start date
Oct 17, 2019
Primary completion
Mar 29, 2022
Completion
Mar 29, 2022
Results posted
Mar 15, 2023
Last update
Nov 4, 2025

Study contacts

Peter Langmuir, MD
study director · Incyte Corporation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pemigatinib

Start the discussion